FDA ODAC Meeting Considers Adequacy of Proposed Trial Design to Later Evaluate Drug Efficacy

An atypical FDA advisory meeting raised serious questions about trial design, evidence, and how cancer drugs get approved—issues with implications well beyond a single drug.

Your gift is doubled through December 31.

Donate Now

The Food and Drug Administration (FDA) made an atypical move in the February 9, 2023 Oncologic Drugs Advisory Committee (ODAC) meeting.

ODAC is an external advisory committee charged to review and evaluate data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and make recommendations to the Commissioner of Food and Drugs. ODAC meetings are open to the public and are an important way for NBCC advocates to make their voices heard.

The purpose of the February 9 meeting was to discuss an investigational new drug application (IND) for dostarlimab (Jemperli; a PD-1 immune checkpoint inhibitor) for the treatment of patients with a certain type of locally advanced, treatment-naïve rectal cancer.

While not breast cancer related, the implications of this meeting are noteworthy and of importance to NBCC.

Why was this ODAC meeting notable?

Instead of being asked to assess the merits of data from a clinical trial of a new cancer treatment, ODAC was asked to consider the adequacy of a proposed trial design that would later be used to evaluate efficacy of the drug in approval for a type of rectal cancer. Currently, the drug is only approved in the advanced/metastatic setting for endometrial cancer.

Why is the trial design so controversial?

First, the proposed trials (one of which is already underway) are single-arm trials (not randomized controlled trials), meaning there is no meaningful control group to compare the drug to.

Second, the current standard of care (SOC) for this type of rectal cancer (i.e., chemotherapy, radiation, and surgery) is curative, meaning these patients can be cured with the current SOC.

Third, the proposed primary endpoint is complete clinical response rate (cCR) at 12 months, which arguably means very little in terms of actual benefit to the patient over the long term.

Fourth, the two trials combined only seek to enroll a total of 130 patients, and previously published preliminary data are available for only 12 patients.

With these limitations in the trial designs, why is the FDA considering this request?

First, the specific type of rectal cancer being addressed is rare, meaning that recruiting higher numbers of patients is difficult.

Second, preliminary data showed that 100% of the 12 patients receiving the experimental drug have achieved complete clinical response, and none of the 12 have needed surgery or chemoradiotherapy to date. These preliminary results are certainly impressive.

Third, the current SOC for this form of rectal cancer causes significant, long-term quality-of-life issues, including infertility, decreased sexual function, and decreased bowel function. Because the SOC causes these severe side effects, investigators believe patients would be hesitant to join a trial where they could be randomized into the SOC arm instead of the experimental arm which doesn’t require surgery and the associated quality of life issues.

Fourth, while the primary endpoint (cCR) is not very meaningful in terms of long-term benefit to the patient, one of the proposed studies plans to analyze event-free survival (EFS) at 3 years and overall survival (OS) at 5 years.

What did ODAC ultimately decide?

After over 6 hours of discussion, ODAC voted 8-5 in support of the proposed trial design. Supporters acknowledged their concerns, but ultimately voted yes because they believe a randomized trial is not feasible in this specific scenario and they believe the data will be sufficient assuming that the proposed trials continue to show substantial clinical response rates. Those who voted no acknowledged the drug’s promise but said the flaws in the design and suboptimal primary endpoints have major consequences for data interpretation and long-term applicability. Ultimately, the final decision is up to the FDA.

NBCC applauds FDA for bringing this question to ODAC and pursuing transparency and a high bar for clinical trial designs. However, if FDA chooses to accept this design, it will set a dangerous precedent that lowers the bar for FDA approval in future trials in the curative setting.

While this ODAC meeting did not deal with a breast cancer drug, both the unprecedented nature of the meeting and FDA’s ultimate decision will mold the future of the drug approval process, including the potential for breast cancer drugs to be approved on the basis of weakly designed, nonrandomized clinical trials.

Patients should be able to make decisions based on meaningful outcomes from robustly designed and conducted clinical trials. Without an appropriate control arm, it is not possible to generate the type of evidence required to support informed decision-making.


Sources

  • Research, C. for D. E. and. Oncologic Drugs Advisory Committee. FDA. fda.gov
  • FDA. UPDATED INFORMATION: February 9, 2023: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. FDA. fda.gov
  • Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363–2376. https://doi.org/10.1056/NEJMoa2201445